CorMedix Inc
Research CorMedix Inc (CRMD) on Bullrun: market cap USD 664.83M, P/E 4.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRMD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 664.83M
- P/E4.1
- Financial periodQ1 2026
- RevenueUSD 400.05M
- Net incomeUSD 181.01M
- Free cash flowUSD 41.65M
- Gross margin26.3%
Valuation Snapshot
latest market cap is USD 664.83M; P/E is 4.1.
Peer valuation comparison
Latest P/E is 4.07x versus a Healthcare sector median of 24.46x (83.4% below).
Latest P/E is 4.07x versus a United States median of 24.87x (83.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 311.71M | USD 163.06M | USD 172.79M | 88.5% | 2.04 | USD 144.84M | USD 148.91M | USD 405.31M |
| FY2024 | USD 43.47M | -USD 17.93M | -USD 50.73M | 92.7% | -0.3 | USD 40.65M | USD 517.00K | USD 84.66M |
| FY2023 | n/a | -USD 46.34M | -USD 38.74M | n/a | -0.91 | USD 43.64M | USD 667.63K | USD 70.14M |
| FY2022 | USD 65.41K | -USD 29.70M | -USD 24.58M | 94.3% | -0.74 | USD 43.15M | USD 864.26K | USD 55.06M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 664.83M | 4.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 921.80M | 5.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 521.73M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 206.09M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 174.21M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 173.29M | n/a | n/a | n/a |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CorMedix Inc's market cap?
CorMedix Inc's market capitalization is USD 664.83M.
What is CorMedix Inc's P/E ratio?
CorMedix Inc's price-to-earnings (P/E) ratio is 4.1.
What does CorMedix Inc do?
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.